A panoply of errors: Polymerase proofreading domain mutations in cancer

Nature Reviews Cancer

Volumn 16, Issue 2, 2016, Pages 71-81

  Rayner, Emily ^a   Van Gool, Inge C ^b   Palles, Claire ^a   Kearsey, Stephen E ^c   Bosse, Tjalling ^b   Tomlinson, Ian ^a   Church, David N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED DNA POLYMERASE DELTA; DNA DIRECTED DNA POLYMERASE EPSILON; DNA POLYMERASE; TUMOR MARKER; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED DNA POLYMERASE GAMMA; POLD1 PROTEIN, HUMAN; POLE PROTEIN, HUMAN;

ALLELE; AMINO ACID SUBSTITUTION; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CELL CYCLE CHECKPOINT; DNA BINDING; DNA REPLICATION; DNA STRAND; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVE SITE; EXCISION REPAIR; GASTROINTESTINAL POLYPOSIS; GENE MUTATION; GENOMIC INSTABILITY; GERMLINE MUTATION; GLIOBLASTOMA; HAPLOTYPE; HUMAN; IMMUNOGENICITY; INDEL MUTATION; LUNG ADENOCARCINOMA; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; MUTATION RATE; NEOPLASM; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; OVARY CANCER; PANCREAS CANCER; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN TARGETING; REVIEW; SOMATIC MUTATION; STOMACH CANCER; ENDOMETRIUM TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS; SACCHAROMYCES CEREVISIAE;

DNA POLYMERASE II; DNA POLYMERASE III; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS; PROGNOSIS; SACCHAROMYCES CEREVISIAE;

EID: 84956649826     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2015.12     Document Type: Review

References (121)

1. Loeb, L. A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075-3079 (1991).
2. Kunkel, T. A. DNA replication fidelity. J. Biol. Chem. 279, 16895-16898 (2004).
3. Loeb, L. A. & Monnat, R. J. DNA polymerases and human disease. Nat. Rev. Genet. 9, 594-604 (2008).
4. Morrison, A., Johnson, A. L., Johnston, L. H. & Sugino, A. Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J. 12, 1467-1473 (1993).
5. Edelmann, W. et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91, 467-477 (1997).
6. Albertson, T. M. et al. DNA polymerase ε and δ proofreading suppress discrete mutator and cancer phenotypes in mice. Proc. Natl Acad. Sci. USA 106, 17101-17104 (2009).
7. Goldsby, R. E. et al. High incidence of epithelial cancers in mice deficient for DNA polymerase δ proofreading. Proc. Natl Acad. Sci. USA 99, 15560-15565 (2002).
8. Goldsby, R. E. et al. Defective DNA polymerase-δ proofreading causes cancer susceptibility in mice. Nat. Med. 7, 638-639 (2001).
9. Fishel, R. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027-1038 (1993).
10. Aaltonen, L. A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812-816 (1993).
11. Yoshida, R. et al. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur. J. Hum. Genet. 19, 320-325 (2011).
12. Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136-144 (2012).
13. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
14. Erson-Omay, E. Z. et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro Oncol. 17, 1356-1364 (2015).
15. Church, D. N. et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum. Mol. Genet. 22, 2820-2828 (2013).
16. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012).
17. The Cancer Genome Atlas Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
18. Shinbrot, E. et al. Exonuclease mutations in DNA polymerase ε reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 24, 1740-1750 (2014).
19. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
20. Church, D. N. et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl Cancer Inst. 107, 1-8 (2015).
21. Billingsley, C. C. et al. Polymerase ε (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121, 386-394 (2014).
22. Stelloo, E. et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod. Pathol. 28, 836-844 (2015).
23. Talhouk, A. et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 113, 299-310 (2015).
24. Meng, B. et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol. Oncol. 134, 15-19 (2014).
25. van Gool, I. C. et al. POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer. Clin. Cancer Res. 21, 3347-3355 (2015).
26. Howitt, B. E. et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1, 1319-1323 (2015).
27. Henninger, E. E. & Pursell, Z. F. DNA polymerase ε and its roles in genome stability. IUBMB Life 66, 339-351 (2014).
28. Prindle, M. J. & Loeb, L. A. DNA polymerase delta in DNA replication and genome maintenance. Env. Mol. Mutag. 53, 666-682 (2012).
29. Pavlov, Y. I. & Shcherbakova, P. V. DNA polymerases at the eukaryotic fork - 20 years later. Mutat. Res. 685, 45-53 (2010).
30. Johansson, E. & Dixon, N. Replicative DNA polymerases. Cold Spring Harb. Perspect. Biol. 5, a012799 (2013).
31. Morrison, A., Araki, H., Clark, A. B., Hamatake, R. K. & Sugino, A. A third essential DNA polymerase in S. cerevisiae. Cell 62, 1143-1151 (1990).
32. Budd, M. & Campbell, J. L. Temperature-sensitive mutations in the yeast DNA polymerase I gene. Proc. Natl Acad. Sci. USA 84, 2838-2842 (1987).
33. Budd, M. E. & Campbell, J. L. DNA polymerases δ and ε are required for chromosomal replication in Saccharomyces cerevisiae. Mol. Cell. Biol. 13, 496-505 (1993).
34. Francesconi, S., Park, H. & Wang, T. S. Fission yeast with DNA polymerase δ temperature-sensitive alleles exhibits cell division cycle phenotype. Nucleic Acids Res. 21, 3821-3828 (1993).
35. Bernad, A., Blanco, L., Lázaro, J., Martín, G. & Salas, M. A conserved 3′→5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell 59, 219-228 (1989).
36. Shevelev, I. V. & Hübscher, U. The 3′5′ exonucleases. Nat. Rev. Mol. Cell Biol. 3, 364-376 (2002).
37. Baranovskiy, A. G. et al. X-ray structure of the complex of regulatory subunits of human DNA polymerase δ. Cell Cycle 7, 3026-3036 (2008).
38. Podust, V. N., Chang, L. S., Ott, R., Dianov, G. L. & Fanning, E. Reconstitution of human DNA polymerase δ using recombinant baculoviruses: the p12 subunit potentiates DNA polymerizing activity of the four-subunit enzyme. J. Biol. Chem. 277, 3894-3901 (2002).
39. Zhou, Y., Meng, X., Zhang, S., Lee, E. Y. & Lee, M. Y. Characterization of human DNA polymerase δ and its subassemblies reconstituted by expression in the MultiBac system. PLoS ONE 7, e319156 (2012).
40. Garbacz, M. et al. Fidelity consequences of the impaired interaction between DNA polymerase ε and the GINS complex. DNA Repair 29, 23-35 (2015).
41. Langston, L. D. et al. CMG helicase and DNA polymerase ε form a functional 15-subunit holoenzyme for eukaryotic leading-strand DNA replication. Proc. Natl Acad. Sci. USA 111, 15390-15395 (2014).
42. Sengupta, S., van Deursen, F., de Piccoli, G. & Labib, K. Dpb2 integrates the leading-strand DNA polymerase into the eukaryotic replisome. Curr. Biol. 23, 543-552 (2013).
43. Aksenova, A. et al. Mismatch repair-independent increase in spontaneous mutagenesis in yeast lacking non-essential subunits of DNA polymerase ε. PLoS Genet. 6, e1001209 (2010).
44. Pursell, Z. F., Isoz, I., Lundström, E.-B., Johansson, E. & Kunkel, T. A. Yeast DNA polymerase ε participates in leading-strand DNA replication. Science 317, 127-130 (2007).
45. McElhinny, S. A., Gordenin, D. A., Stith, C. M., Burgers, P. M. J. & Kunkel, T. A. Division of labor at the eukaryotic replication fork. Mol. Cell 30, 137-144 (2008).
46. Miyabe, I., Kunkel, T. A. & Carr, A. M. The major roles of DNA polymerases ε and δ at the eukaryotic replication fork are evolutionarily conserved. PLoS Genet. 7, e1002407 (2011).
47. Vazquez, E. & Antequera, F. Replication dynamics in fission and budding yeasts through DNA polymerase tracking. Bioessays 37, 1067-1073 (2015).
48. Georgescu, R. E. et al. Reconstitution of a eukaryotic replisome reveals suppression mechanisms that define leading/lagging strand operation. eLife 4, e04988 (2015).
49. Georgescu, R. E. et al. Mechanism of asymmetric polymerase assembly at the eukaryotic replication fork. Nat. Struct. Mol. Biol. 21, 664-670 (2014).
50. Hogg, M. et al. Structural basis for processive DNA synthesis by yeast DNA polymerase ε. Nat. Struct. Mol. Biol. 21, 49-55 (2014).
51. Johnson, Robert, E., Klassen, R., Prakash, L. & Prakash, S. A major role of DNA polymerase δ in replication of both the leading and lagging DNA strands. Mol. Cell 59, 163-175 (2015).
52. Blank, A., Kim, B. Fau - Loeb, L. A. & Loeb, L. A. DNA polymerase δ is required for base excision repair of DNA methylation damage in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 91, 9047-9051 (1994).
53. Stucki, M. et al. Mammalian base excision repair by DNA polymerases δ and ε. Oncogene 17, 835-843 (1998).
54. Nishida, C., Reinhard, P. & Linn, S. DNA repair synthesis in human fibroblasts requires DNA polymerase δ. J. Biol. Chem. 263, 501-510 (1988).
55. Lehmann, A. R. DNA polymerases and repair synthesis in NER in human cells. DNA Repair 10, 730-733 (2011).
56. Tran, H. T., Gordenin, D. A. & Resnick, M. A. The 3′→5′ exonucleases of DNA polymerases δ and ε and the 5′→3′ exonuclease Exo1 have major roles in postreplication mutation avoidance in Saccharomyces cerevisiae. Mol. Cell. Biol. 19, 2000-2007 (1999).
57. Bowen, N. et al. Reconstitution of long and short patch mismatch repair reactions using Saccharomyces cerevisiae proteins. Proc. Natl Acad. Sci. USA 110, 18472-18477 (2013).
58. Zhang, Y. et al. Reconstitution of 5′-directed human mismatch repair in a purified system. Cell 122, 693-705 (2005).
59. Costantino, L. et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science 343, 88-91 (2014).
60. Lydeard, J. R., Jain, S., Yamaguchi, M. & Haber, J. E. Break-induced replication and telomerase-independent telomere maintenance require Pol32. Nature 448, 820-823 (2007).
61. Pursell, Z. F. & Kunkel, T. A. DNA polymerase ε: a polymerase of unusual size (and complexity). Prog. Nucleic Acid Res. Mol. Biol. 82, 101-145 (2008).
62. Ganai, R. a., Bylund, G. O. & Johansson, E. Switching between polymerase and exonuclease sites in DNA polymerase ε. Nucleic Acids Res. 4, 1-11 (2014).
63. Simon, M., Giot, L. & Faye, G. The 3′ to 5′ exonuclease activity located in the DNA polymerase delta subunit of Saccharomyces cerevisiae is required for accurate replication. EMBO J. 10, 2165-2170 (1991).
64. Murphy, K., Darmawan, H., Schultz, A., da Silva, E. F. & Reha-Krantz, L. J. A method to select for mutator DNA polymerase δs in Saccharomyces cerevisiae. Genome 49, 403-410 (2006).
65. Datta, A. et al. Checkpoint-dependent activation of mutagenic repair in Saccharomyces cerevisiae pol3-01 mutants. Mol. Cell 6, 593-603 (2000).
66. Williams, L. N. et al. dNTP pool levels modulate mutator phenotypes of error-prone DNA polymerase ε variants. Proc. Natl Acad. Sci. USA 112, E2457-E2466 (2015).
67. Bellido, F. et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet. Med. https://dx.doi.org/10.1038/gim.2015.75 (2015).
68. Spier, I. et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int. J. Cancer 137, 320-331 (2015).
69. Chubb, D. et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J. Clin. Oncol. 33, 426-432 (2015).
70. Valle, L. et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum. Mol. Genet. 23, 3506-3512 (2014).
71. Elsayed, F. A. et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur. J. Hum. Genet. 23, 1080-1084 (2015).
72. Rohlin, A. et al. A mutation in POLE predisposing to a multi-tumour phenotype. Int. J. Oncol. 45, 77-81 (2014).
73. Hansen, M. F. et al. A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. Fam. Cancer 14, 437-448 (2015).
74. Aoude, L. G. et al. POLE mutations in families predisposed to cutaneous melanoma. Fam. Cancer 14, 621-628 (2015).
75. Zou, Y. et al. Frequent POLE1 p. S297F mutation in Chinese patients with ovarian endometrioid carcinoma. Mutat. Res. 761, 49-52 (2014).
76. Jones, S. et al. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat. Commun. 5, 5006 (2014).
77. Shlien, A. et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47, 257-262 (2015).
78. The Cancer Genome Atlas Network. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014).
79. The Cancer Genome Atlas Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014).
80. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
81. The Cancer Genome Atlas Network. Comprehensive molecular profiling of lung adenocarcinomas. Nature 511, 543-550 (2014).
82. Kane, D. P. & Shcherbakova, P. V. A common cancer-associated DNA polymerase ε mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res. 74, 1895-1901 (2014).
83. Hussein, Y. R. et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod. Pathol. 28, 505-514 (2014).
84. Bertagnolli, M. M. et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer - a study of CALGB 9581 and 89803. J. Clin. Oncol. 29, 3153-3162 (2011).
85. Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261-1270 (2011).
86. Nelson, G. S. et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol. Oncol. 131, 309-314 (2013).
87. Diaz-Padilla, I. et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 88, 154-167 (2013).
88. Heitzer, E. & Tomlinson, I. Replicative DNA polymerase mutations in cancer. Curr. Opin. Genet. Dev. 24, 107-113 (2014).
89. Williams, L. N., Herr, A. J. & Preston, B. D. Emergence of DNA polymerase ε antimutators that escape error-induced extinction in yeast. Genetics 193, 751-770 (2013).
90. Herr, A. J., Kennedy, S. R., Knowels, G. M., Schultz, E. M. & Preston, B. D. DNA replication error-induced extinction of diploid yeast. Genetics 196, 677-691 (2014).
91. Heyer, J., Yang, K., Lipkin, M., Edelmann, W. & Kucherlapati, R. Mouse models for colorectal cancer. Oncogene 18, 5325-5333 (1999).
92. Sole, R. V. & Deisboeck, T. S. An error catastrophe in cancer? J. Theor. Biol. 228, 47-54 (2004).
93. Loeb, L. A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer 11, 450-457 (2011).
94. Herr, A. J. et al. Mutator suppression and escape from replication error-induced extinction in yeast. PLoS Genet. 7, e1002282 (2011).
95. Ghodgaonkar, M. M. et al. Phenotypic characterization of missense polymerase-δ mutations using an inducible protein-replacement system. Nat. Commun. 5, 4990-4990 (2014).
96. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
97. Korona, D. A., LeCompte, K. G. & Pursell, Z. F. The high fidelity and unique error signature of human DNA polymerase. Nucleic Acids Res. 39, 1763-1773 (2011).
98. Schwarz, J. M., Cooper, D. N. Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11, 361-362 (2014).
99. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073-1081 (2009).
100. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
101. Fox, E. J., Prindle, M. J. & Loeb, L. A. Do mutator mutations fuel tumorigenesis? Cancer Metastasis Rev. 32, 353-361 (2013).
102. Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43-51 (2015).
103. McFarland, C. D., Mirny, L. A. & Korolev, K. S. Tug-of-war between driver and passenger mutationsin cancer and other adaptive processes. Proc. Natl Acad. Sci. USA 111, 15138-15143 (2014).
104. Vasen, H. F. et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62, 812-823 (2013).
105. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
106. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
107. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
108. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
109. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
110. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
111. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015).
112. Jin, Y. H. et al. Cadmium is a mutagen that acts by inhibiting mismatch repair. Nat. Genet. 34, 326-329 (2003).
113. Mertz, T. M., Sharma, S., Chabes, A. & Shcherbakova, P. V. Colon cancer-associated mutator DNA polymerase δ variant causes expansion of dNTP pools increasing its own infidelity. Proc. Natl Acad. Sci. USA 112, E2467-E2476 (2015).
114. Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726-736 (2015).
115. Loeb, L. A., Bielas, J. H. & Beckman, R. A. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 68, 3551-3557 (2008).
116. Swan, M. K., Johnson, R. E., Prakash, L., Prakash, S. & Aggarwal, A. K. Structural basis of high-fidelity DNA synthesis by yeast DNA polymerase δ. Nat. Struct. Mol. Biol. 16, 979-986 (2009).
117. 2-terminal fragment of T4 DNA polymerase and its complexes with single-stranded DNA and with divalent metal ions. Biochemistry 35, 8110-8119 (1996).
118. Hoang, L. N. et al. Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int. J. Gynecol. Cancer 25, 1187-1193 (2015).
119. Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2014).
120. Abdus Sattar, A. K., Lin, T. C., Jones, C. & Konigsberg, W. H. Functional consequences and exonuclease kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. Biochemistry 35, 16621-16629 (1996).
121. Stenzinger, A. et al. Mutations in POLE and survival of colorectal cancer patients - link to disease stage and treatment. Cancer Med. 3, 1527-1538 (2014).